Literature DB >> 19916856

Movement disorders associated with aripiprazole use: a case series.

Deborah A Hall1, Pinky Agarwal, Alida Griffith, Vicki Segro, Lauren C Seeberger.   

Abstract

Aripiprazole is an atypical antipsychotic that is a partial agonist at the D2 and 5HT1a receptors and an antagonist at 5HT2a receptors. Despite previous hypotheses that it would be less likely to cause movement disorders, recent reports suggest it actually may be more likely to cause movement disorders than other atypical antipsychotics. This case series illustrates the variety of movement disorders associated with aripiprazole use at three movement disorder clinics. It also suggests that aripiprazole be used with caution in patients with a prior history of dystonia, parkinsonism, or previous tardive dyskinesia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19916856     DOI: 10.3109/00207450903225553

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  6 in total

Review 1.  Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group.

Authors:  Pasquale De Fazio; Paolo Girardi; Giuseppe Maina; Massimo Carlo Mauri; Mauro Mauri; Palmiero Monteleone; Giulia Ida Perini; Giulio Perugi; Alessandro Rossi
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Association of Parkinsonism or Parkinson Disease with Polypharmacy in the Year Preceding Diagnosis: A Nested Case-Control Study in South Korea.

Authors:  Hae-Young Park; Ji-Won Park; Hyun Soon Sohn; Jin-Won Kwon
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

3.  A case of aripiprazole induced tardive dyskinesia in a neuroleptic-naïve patient with two years of follow up.

Authors:  Rakesh Goyal; Salam Hemabati Devi
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-04-24       Impact factor: 2.582

4.  Parkinsonism and cognitive decline in a fragile X mosaic male.

Authors:  Deborah Hall; Laura Pickler; Karen Riley; Flora Tassone; Randi Hagerman
Journal:  Mov Disord       Date:  2010-07-30       Impact factor: 10.338

5.  Effect of psychotropic drug treatment on sterol metabolism.

Authors:  Željka Korade; Wei Liu; Emily B Warren; Kristan Armstrong; Ned A Porter; Christine Konradi
Journal:  Schizophr Res       Date:  2017-02-12       Impact factor: 4.939

6.  Neuroleptic malignant syndrome: a review for neurohospitalists.

Authors:  Brian D Berman
Journal:  Neurohospitalist       Date:  2011-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.